<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370847</url>
  </required_header>
  <id_info>
    <org_study_id>MD.19.10.235</org_study_id>
    <nct_id>NCT04370847</nct_id>
  </id_info>
  <brief_title>Ultrasonography for Fluid Assessment in Parturients With Preeclampsia Undergoing Cesarean Section</brief_title>
  <official_title>Ultrasonography for Fluid Assessment in Parturients With Preeclampsia Undergoing Elective Cesarean Section Under Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia is a multifocal syndrome reported in 2-8 % of pregnancies. It is diagnosed in&#xD;
      the second half of pregnancy by two separate measurements of systolic blood pressure ≥140&#xD;
      mmHg and/or a diastolic blood pressure ≥ 90 mmHg in the same arm and proteinuria &gt;300 mg in&#xD;
      24 h urine collection. The risk for serious complications such as pulmonary edema,&#xD;
      cerebrovascular accidents, coagulopathy, and hemorrhage is 10 to 30 fold higher among&#xD;
      parturients with severe preeclampsia.&#xD;
&#xD;
      Severe preeclampsia is defined by one or more of the following clinical features: severe&#xD;
      hypertension (systolic arterial pressure 160 mmHg and/or diastolic arterial pressure 110 mmHg&#xD;
      on more than one occasion at least 4 h apart while the patient is on bed rest, renal&#xD;
      dysfunction (serum creatinine &gt;1.1mg/dl or doubling of serum creatinine in the absence of&#xD;
      another renal disease, platelet count less than &lt;100,000 mm3, acute pulmonary edema,&#xD;
      epigastric pain not responding to medical treatment, new-onset cerebral and visual&#xD;
      manifestation, hemolysis, elevated liver enzymes and low platelet count syndrome (HELLP&#xD;
      syndrome)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluid resuscitation is a key determinant in the management of these parturients. Hypovolemia&#xD;
      exacerbates organ failure, whereas volume overload results in pulmonary edema. In this&#xD;
      setting, the use of noninvasive hemodynamic monitoring is associated with reduced mortality.&#xD;
&#xD;
      Point-of-care lung ultrasonography is used in many critical care settings as the initial&#xD;
      diagnostic imaging study for patients with respiratory symptoms. It is highly sensitive for&#xD;
      the diagnosis of pulmonary edema which may occur even without cardiomyopathy or heart&#xD;
      failure.&#xD;
&#xD;
      The IVC is a highly compliant vessel that changes its diam¬eter in parallel with changes in&#xD;
      blood volume and central venous pressure. Measurement of IVC diameter and col¬lapsibility&#xD;
      index using ultrasound through a subcostal approach has been investigated in patients of&#xD;
      various settings. The IVC-CI imaging technique may be used to assess the volume status in&#xD;
      healthy parturients undergoing routine cesarean delivery as well as in high-risk parturients&#xD;
      as preeclampsia.&#xD;
&#xD;
      Cerebral edema is predominantly vasogenic and may be related to the failure of cerebral&#xD;
      autoregulation with subsequent hyperperfusion, blood-brain barrier disruption, and&#xD;
      endothelial cell dysfunction. Ultrasonographic measurements of the optic nerve sheath&#xD;
      diameter (ONSD) correlate with signs of raised ICP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasonographic fluid assessment</measure>
    <time_frame>Time frame:preoperative(baseline) and 2 hours after spinal anesthesia.</time_frame>
    <description>Detection of change in overall number of B lines (ECS) by lung ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>For 2 hours after spinal anesthesia</time_frame>
    <description>total urine output at 2 hours after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oliguria</measure>
    <time_frame>For 2 hours after spinal anesthesia</time_frame>
    <description>Incidence of oliguria defined as a total urine output &lt;60 mL/hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ephedrine use</measure>
    <time_frame>Intraoperative</time_frame>
    <description>total ephedrine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative bradycardia</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Incidence of bradycardia (Heart rate &lt;50 beats/minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nausea and vomiting.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Incidence of nausea and/or vomiting as reported by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between overall number of b lines</measure>
    <time_frame>baseline and 1hour post spinal</time_frame>
    <description>difference between overall number of b lines preoperative(baseline) and at 1 hour after spinal anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inferior Vena Caval Diameters</measure>
    <time_frame>Baseline, and at 1 and 2 hours post-spinal</time_frame>
    <description>Maximum, minimum inferior vena cava diameters and inferior vena cava collapsibility index changes over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between optic nerve sheath diameter</measure>
    <time_frame>baseline,at 1hour and at 2 hours of spinal anesthesia.</time_frame>
    <description>optic nerve sheath diameter changes over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Apgar score</measure>
    <time_frame>5 min after delivery</time_frame>
    <description>neonatal Apgar score to assess neonatal wellbeing at 5 min after delivery</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Elective Cesarean Section</condition>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
    <description>Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spinal Anesthesia</intervention_name>
    <description>Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal Bupivacaine</intervention_name>
    <description>Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal Fentanyl</intervention_name>
    <description>Fentanyl 15 μg will be administered in the subarachnoid space</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cesarean Delivery</intervention_name>
    <description>Lower segment cesarean section using the Pfannenstiel incision</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>lung ultrasound scans</intervention_name>
    <description>lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultrasound Assessment of the Inferior Vena Cava</intervention_name>
    <description>The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optic nerve sheath diameter</intervention_name>
    <description>Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ringer acetate</intervention_name>
    <description>1000 ml ringer acetate will be administered over 2 hours.</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Ephedrine</intervention_name>
    <description>Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Syntocinon</intervention_name>
    <description>Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.</description>
    <arm_group_label>Lung Ultrasound (LUS) Examination</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The calculated sample size of the study will be 70 parturients at 5% level of significance&#xD;
        and 80 % power, using the following formula:&#xD;
&#xD;
        N= (Z1-α/2+Z1-β) ² σ1* σ2 / δ ² *2 Z1-α/2 = 1.96 Z1-β= 0.842 σ = SD (8, 9) δ = Expected&#xD;
        difference to be detected before and after delivery (4). α = Level of acceptability of a&#xD;
        false positive result (level of significance=0.05).&#xD;
&#xD;
        β = Level of acceptability of a false negative result (0.20).&#xD;
&#xD;
        1- β= power (0.80).The sample size will be increased to 100 parturients to compensate for&#xD;
        protocol failures with incomplete data and to increase the power of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy.&#xD;
&#xD;
          -  32 - 41 weeks gestational age.&#xD;
&#xD;
          -  Preeclampsia: Blood Pressure ≥140/90 mmHg after 20 weeks' gestation and proteinuria&#xD;
             ≥300 mg/24 hours or 1+ on urine dipstick&#xD;
&#xD;
          -  Elective cesarean delivery under spinal anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥40 kg/m2.&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Other obstetrical problems&#xD;
&#xD;
          -  Other uteroplacental problems&#xD;
&#xD;
          -  Abruption placenta.&#xD;
&#xD;
          -  Already treated for acute lung pathology prior to enrollment.&#xD;
&#xD;
          -  Contraindications to spinal anesthesia.&#xD;
&#xD;
          -  INR &gt;1.5 or PLT&lt;100,000 /mm3.&#xD;
&#xD;
          -  Women presenting in labor.&#xD;
&#xD;
          -  Previous thoracic surgery.&#xD;
&#xD;
          -  Previous ocular surgery&#xD;
&#xD;
          -  Ocular trauma&#xD;
&#xD;
          -  Glaucoma.&#xD;
&#xD;
          -  Preoperative pulmonary disease:&#xD;
&#xD;
          -  Increased serum creatinine level ≥1.1 mg/dL.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Aboelnour E Aboelnour, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor of Anesthesia and Surgical Intensive care,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanaa A Elbendary, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor, MD anesthesia Department, Faculty of Medicine, Mansoura University, Egypt.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marwa L Abdo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>lecturer of Anesthesia and Surgical Intensive care,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aboelnour E Aboelnour, MD</last_name>
    <phone>00201002477789</phone>
    <email>aboelnour@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanaa A Elbendary, MD</last_name>
    <phone>00201005781768</phone>
    <email>hanaa_elbendary@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aboelnour E Badran, MD</last_name>
      <phone>00201227380257</phone>
      <email>aboelnour@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hanaa M Elbendary, MD</last_name>
      <phone>00201005781768</phone>
      <email>hanaa_elbendary@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dina A Elebedy, M.Sec</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The data will be available following publication for life-long.</ipd_time_frame>
    <ipd_access_criteria>the data will be accessible to the investigators .and the PRS administrators with hiding the identifiers for the patients</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

